Increased serum levels of transforming growth factor-α in patients with colorectal cancer

Kang Sup Shim; Kwang Ho Kim; Byeong Woo Park; Sun Young Yi; Jin Hyuk Choi; Woon Sup Han; Eung Bum Park

doi:10.1007/BF02238252

Increased serum levels of transforming growth factor-α in patients with colorectal cancer

Kang Sup Shim, Kwang Ho Kim, Byeong Woo Park, Sun Young Yi, Jin Hyuk Choi, Woon Sup Han, Eung Bum Park

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

PURPOSE: This study was conducted to investigate the serum levels of transforming growth factor-α in patients with colorectal cancer and to investigate the clinical significance of these levels in association with tumor stage and histologic differentiation. Also, serum levels of transforming growth factor-α were measured after curative surgical resection. METHODS: Serum levels of transforming growth factor-α were measured in 42 consecutive patients with colorectal cancer before surgery, in 21 patients after surgical resection (part of the 42 preoperative patients), and in 20 healthy volunteers. We used TGF-α Assay(TM). RESULTS: Serum levels of transforming growth factor-α in patients with colorectal cancer were significantly higher than in the healthy control group (P = 0.001). Significant elevations in serum levels of transforming growth factor-α were found in 50 percent (21/42) of patients with colorectal cancer when the mean + 2 standard deviations (80.4 pg/ml) of the control group were used as the upper limit of the normal range. Serum levels of transforming growth factor- α tended to decrease with increasing tumor size (n = 31; r = -0.52; P = 0.002). Serum levels of transforming growth factor-α before surgery (89.7 ± 44.4 pg/ml; n = 21) significantly decreased to 60.3 ± 19.8 pg/ml after surgical resections of tumors (P = 0.017). Serum levels of transforming growth factor-α completely decreased to the same serum levels of the control group after surgical resections in all patients who had serum levels of transforming growth factor-α greater than mean + 2 standard deviations (80.4 pg/ml) of the control group preoperatively (n = 11; P = 0.002). CONCLUSIONS: Levels of preoperative transforming growth factor-α in patients with colorectal cancer appeared to be higher than levels measured in control subjects. Serum levels of transforming growth factor-a before surgery significantly decreased after surgical resections of tumors. Additional studies are warranted to determine if serum levels of transforming growth factor-α may be useful as a potential biomarker in the management of patients with colorectal cancer.

Original language	English
Pages (from-to)	219-224
Number of pages	6
Journal	Diseases of the Colon and Rectum
Volume	41
Issue number	2
DOIs	https://doi.org/10.1007/BF02238252
State	Published - Feb 1998

Bibliographical note

Funding Information:
PURPOSE: This study was conducted to investigate the serum levels of transforming growth factor-a in patients with colorectal cancer and to investigate the clinical significance of these levels in association with tumor stage and histologic differentiation. Also, serum levels of transforming growth factor-a were measured after curative surgical resection. METHODS: Serum levels of transforming growth factor<z were measured in 42 consecutive patients with colorectal cancer before surgery, in 21 patients after surgical resection (part of the 42 preoperative patients), and in 20 healthy volunteers. We used TGF-c~ AssayT M. RESULTS: Serum levels of transforming growth factor-cz in patients with colorectal cancer were significantly higher than in the healthy control group (P = 0.001). Significant elevations in serum levels of transforming growth factor-~ were found in 50 percent (21/42) of patients with colorectal cancer when the mean + 2 standard deviations (80.4 pg/ml) of the control group were used as the upper limit of the normal range. Serum levels of transforming growth factor-cz tended to decrease with increasing tumor size (n = 31; r = -0.52; P = 0.002). Serum levels of transforming growth factor-0t before surgery (89.7 + 44.4 pg/ml; n = 21) significantly decreased to 60.3 +-19.8 pg/ml after surgical resections of tumors (P --0.017). Serum levels of transforming growth factor-oe completely decreased to the same serum levels of the control group after surgical resections in all patients who had serum levels of transforming growth factor-a greater than mean + 2 standard deviations (80.4 pg/ird) of the control group preoperatively (n = 11; P = 0.002). CONCLUSIONS: Levels of preoperative transforming growth factor<z in patients with colorectal cancer appeared to be higher than levels measured in control subjects. Serum levels of transforming growth factor<z before surgery significantly decreased after surgical resections of tumors. Additional studies are warranted to determine if serum levels of transforming growth factor-a may be useful as a potential biomarker in the management of patients with colorectal cancer. [Key words: Colorectal cancer; Transforming growth factor-a; Enzyme-linked immunoadsorbent assay; Serum] Supported by a grant from Ewha Womans University Mokdong Hospital, Seoul, Korea. Read at the meeting of The American Society of Colon and Rectal Surgeons, Philadelphia, Pennsylvania, June 22 to 26, 1997. Address reprint requests to Dr. Shim: Department of General Sur-gel-y, Ewha Womans University Mokdong Hospital, 911-1 Mok-dong, YangCheon-Ku, Seoul, Korea.

Keywords

Colorectal cancer
Enzyme-linked immunoadsorbent assay
Serum
Transforming growth factor-α

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/BF02238252

Cite this

@article{1f8fe4079e0d47fe911f1c91b42a6e59,

title = "Increased serum levels of transforming growth factor-α in patients with colorectal cancer",

abstract = "PURPOSE: This study was conducted to investigate the serum levels of transforming growth factor-α in patients with colorectal cancer and to investigate the clinical significance of these levels in association with tumor stage and histologic differentiation. Also, serum levels of transforming growth factor-α were measured after curative surgical resection. METHODS: Serum levels of transforming growth factor-α were measured in 42 consecutive patients with colorectal cancer before surgery, in 21 patients after surgical resection (part of the 42 preoperative patients), and in 20 healthy volunteers. We used TGF-α Assay(TM). RESULTS: Serum levels of transforming growth factor-α in patients with colorectal cancer were significantly higher than in the healthy control group (P = 0.001). Significant elevations in serum levels of transforming growth factor-α were found in 50 percent (21/42) of patients with colorectal cancer when the mean + 2 standard deviations (80.4 pg/ml) of the control group were used as the upper limit of the normal range. Serum levels of transforming growth factor- α tended to decrease with increasing tumor size (n = 31; r = -0.52; P = 0.002). Serum levels of transforming growth factor-α before surgery (89.7 ± 44.4 pg/ml; n = 21) significantly decreased to 60.3 ± 19.8 pg/ml after surgical resections of tumors (P = 0.017). Serum levels of transforming growth factor-α completely decreased to the same serum levels of the control group after surgical resections in all patients who had serum levels of transforming growth factor-α greater than mean + 2 standard deviations (80.4 pg/ml) of the control group preoperatively (n = 11; P = 0.002). CONCLUSIONS: Levels of preoperative transforming growth factor-α in patients with colorectal cancer appeared to be higher than levels measured in control subjects. Serum levels of transforming growth factor-a before surgery significantly decreased after surgical resections of tumors. Additional studies are warranted to determine if serum levels of transforming growth factor-α may be useful as a potential biomarker in the management of patients with colorectal cancer.",

keywords = "Colorectal cancer, Enzyme-linked immunoadsorbent assay, Serum, Transforming growth factor-α",

author = "Shim, {Kang Sup} and Kim, {Kwang Ho} and Park, {Byeong Woo} and Yi, {Sun Young} and Choi, {Jin Hyuk} and Han, {Woon Sup} and Park, {Eung Bum}",

note = "Funding Information: PURPOSE: This study was conducted to investigate the serum levels of transforming growth factor-a in patients with colorectal cancer and to investigate the clinical significance of these levels in association with tumor stage and histologic differentiation. Also, serum levels of transforming growth factor-a were measured after curative surgical resection. METHODS: Serum levels of transforming growth factor<z were measured in 42 consecutive patients with colorectal cancer before surgery, in 21 patients after surgical resection (part of the 42 preoperative patients), and in 20 healthy volunteers. We used TGF-c~ AssayT M. RESULTS: Serum levels of transforming growth factor-cz in patients with colorectal cancer were significantly higher than in the healthy control group (P = 0.001). Significant elevations in serum levels of transforming growth factor-~ were found in 50 percent (21/42) of patients with colorectal cancer when the mean + 2 standard deviations (80.4 pg/ml) of the control group were used as the upper limit of the normal range. Serum levels of transforming growth factor-cz tended to decrease with increasing tumor size (n = 31; r = -0.52; P = 0.002). Serum levels of transforming growth factor-0t before surgery (89.7 + 44.4 pg/ml; n = 21) significantly decreased to 60.3 +-19.8 pg/ml after surgical resections of tumors (P --0.017). Serum levels of transforming growth factor-oe completely decreased to the same serum levels of the control group after surgical resections in all patients who had serum levels of transforming growth factor-a greater than mean + 2 standard deviations (80.4 pg/ird) of the control group preoperatively (n = 11; P = 0.002). CONCLUSIONS: Levels of preoperative transforming growth factor<z in patients with colorectal cancer appeared to be higher than levels measured in control subjects. Serum levels of transforming growth factor<z before surgery significantly decreased after surgical resections of tumors. Additional studies are warranted to determine if serum levels of transforming growth factor-a may be useful as a potential biomarker in the management of patients with colorectal cancer. [Key words: Colorectal cancer; Transforming growth factor-a; Enzyme-linked immunoadsorbent assay; Serum] Supported by a grant from Ewha Womans University Mokdong Hospital, Seoul, Korea. Read at the meeting of The American Society of Colon and Rectal Surgeons, Philadelphia, Pennsylvania, June 22 to 26, 1997. Address reprint requests to Dr. Shim: Department of General Sur-gel-y, Ewha Womans University Mokdong Hospital, 911-1 Mok-dong, YangCheon-Ku, Seoul, Korea.",

year = "1998",

month = feb,

doi = "10.1007/BF02238252",

language = "English",

volume = "41",

pages = "219--224",

journal = "Diseases of the Colon and Rectum",

issn = "0012-3706",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "2",

}

TY - JOUR

T1 - Increased serum levels of transforming growth factor-α in patients with colorectal cancer

AU - Shim, Kang Sup

AU - Kim, Kwang Ho

AU - Park, Byeong Woo

AU - Yi, Sun Young

AU - Choi, Jin Hyuk

AU - Han, Woon Sup

AU - Park, Eung Bum

N1 - Funding Information: PURPOSE: This study was conducted to investigate the serum levels of transforming growth factor-a in patients with colorectal cancer and to investigate the clinical significance of these levels in association with tumor stage and histologic differentiation. Also, serum levels of transforming growth factor-a were measured after curative surgical resection. METHODS: Serum levels of transforming growth factor<z were measured in 42 consecutive patients with colorectal cancer before surgery, in 21 patients after surgical resection (part of the 42 preoperative patients), and in 20 healthy volunteers. We used TGF-c~ AssayT M. RESULTS: Serum levels of transforming growth factor-cz in patients with colorectal cancer were significantly higher than in the healthy control group (P = 0.001). Significant elevations in serum levels of transforming growth factor-~ were found in 50 percent (21/42) of patients with colorectal cancer when the mean + 2 standard deviations (80.4 pg/ml) of the control group were used as the upper limit of the normal range. Serum levels of transforming growth factor-cz tended to decrease with increasing tumor size (n = 31; r = -0.52; P = 0.002). Serum levels of transforming growth factor-0t before surgery (89.7 + 44.4 pg/ml; n = 21) significantly decreased to 60.3 +-19.8 pg/ml after surgical resections of tumors (P --0.017). Serum levels of transforming growth factor-oe completely decreased to the same serum levels of the control group after surgical resections in all patients who had serum levels of transforming growth factor-a greater than mean + 2 standard deviations (80.4 pg/ird) of the control group preoperatively (n = 11; P = 0.002). CONCLUSIONS: Levels of preoperative transforming growth factor<z in patients with colorectal cancer appeared to be higher than levels measured in control subjects. Serum levels of transforming growth factor<z before surgery significantly decreased after surgical resections of tumors. Additional studies are warranted to determine if serum levels of transforming growth factor-a may be useful as a potential biomarker in the management of patients with colorectal cancer. [Key words: Colorectal cancer; Transforming growth factor-a; Enzyme-linked immunoadsorbent assay; Serum] Supported by a grant from Ewha Womans University Mokdong Hospital, Seoul, Korea. Read at the meeting of The American Society of Colon and Rectal Surgeons, Philadelphia, Pennsylvania, June 22 to 26, 1997. Address reprint requests to Dr. Shim: Department of General Sur-gel-y, Ewha Womans University Mokdong Hospital, 911-1 Mok-dong, YangCheon-Ku, Seoul, Korea.

PY - 1998/2

Y1 - 1998/2

N2 - PURPOSE: This study was conducted to investigate the serum levels of transforming growth factor-α in patients with colorectal cancer and to investigate the clinical significance of these levels in association with tumor stage and histologic differentiation. Also, serum levels of transforming growth factor-α were measured after curative surgical resection. METHODS: Serum levels of transforming growth factor-α were measured in 42 consecutive patients with colorectal cancer before surgery, in 21 patients after surgical resection (part of the 42 preoperative patients), and in 20 healthy volunteers. We used TGF-α Assay(TM). RESULTS: Serum levels of transforming growth factor-α in patients with colorectal cancer were significantly higher than in the healthy control group (P = 0.001). Significant elevations in serum levels of transforming growth factor-α were found in 50 percent (21/42) of patients with colorectal cancer when the mean + 2 standard deviations (80.4 pg/ml) of the control group were used as the upper limit of the normal range. Serum levels of transforming growth factor- α tended to decrease with increasing tumor size (n = 31; r = -0.52; P = 0.002). Serum levels of transforming growth factor-α before surgery (89.7 ± 44.4 pg/ml; n = 21) significantly decreased to 60.3 ± 19.8 pg/ml after surgical resections of tumors (P = 0.017). Serum levels of transforming growth factor-α completely decreased to the same serum levels of the control group after surgical resections in all patients who had serum levels of transforming growth factor-α greater than mean + 2 standard deviations (80.4 pg/ml) of the control group preoperatively (n = 11; P = 0.002). CONCLUSIONS: Levels of preoperative transforming growth factor-α in patients with colorectal cancer appeared to be higher than levels measured in control subjects. Serum levels of transforming growth factor-a before surgery significantly decreased after surgical resections of tumors. Additional studies are warranted to determine if serum levels of transforming growth factor-α may be useful as a potential biomarker in the management of patients with colorectal cancer.

AB - PURPOSE: This study was conducted to investigate the serum levels of transforming growth factor-α in patients with colorectal cancer and to investigate the clinical significance of these levels in association with tumor stage and histologic differentiation. Also, serum levels of transforming growth factor-α were measured after curative surgical resection. METHODS: Serum levels of transforming growth factor-α were measured in 42 consecutive patients with colorectal cancer before surgery, in 21 patients after surgical resection (part of the 42 preoperative patients), and in 20 healthy volunteers. We used TGF-α Assay(TM). RESULTS: Serum levels of transforming growth factor-α in patients with colorectal cancer were significantly higher than in the healthy control group (P = 0.001). Significant elevations in serum levels of transforming growth factor-α were found in 50 percent (21/42) of patients with colorectal cancer when the mean + 2 standard deviations (80.4 pg/ml) of the control group were used as the upper limit of the normal range. Serum levels of transforming growth factor- α tended to decrease with increasing tumor size (n = 31; r = -0.52; P = 0.002). Serum levels of transforming growth factor-α before surgery (89.7 ± 44.4 pg/ml; n = 21) significantly decreased to 60.3 ± 19.8 pg/ml after surgical resections of tumors (P = 0.017). Serum levels of transforming growth factor-α completely decreased to the same serum levels of the control group after surgical resections in all patients who had serum levels of transforming growth factor-α greater than mean + 2 standard deviations (80.4 pg/ml) of the control group preoperatively (n = 11; P = 0.002). CONCLUSIONS: Levels of preoperative transforming growth factor-α in patients with colorectal cancer appeared to be higher than levels measured in control subjects. Serum levels of transforming growth factor-a before surgery significantly decreased after surgical resections of tumors. Additional studies are warranted to determine if serum levels of transforming growth factor-α may be useful as a potential biomarker in the management of patients with colorectal cancer.

KW - Colorectal cancer

KW - Enzyme-linked immunoadsorbent assay

KW - Serum

KW - Transforming growth factor-α

UR - http://www.scopus.com/inward/record.url?scp=0031941518&partnerID=8YFLogxK

U2 - 10.1007/BF02238252

DO - 10.1007/BF02238252

M3 - Article

C2 - 9556248

AN - SCOPUS:0031941518

SN - 0012-3706

VL - 41

SP - 219

EP - 224

JO - Diseases of the Colon and Rectum

JF - Diseases of the Colon and Rectum

IS - 2

ER -

Increased serum levels of transforming growth factor-α in patients with colorectal cancer

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this